Identification of Uridine Diphosphate Glucuronosyltransferases Involved in the Metabolism and Clearance of Mycophenolic Acid, Therapeutic Drug Monitoring, vol.22, issue.1, 2000. ,
DOI : 10.1097/00007691-200002000-00002
IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM, Drug Metabolism and Disposition, vol.33, issue.1, pp.139-185, 2005. ,
DOI : 10.1124/dmd.104.001651
The Human UDP Glucuronosyltransferase, UGT1A10, Glucuronidates Mycophenolic Acid, Biochemical and Biophysical Research Communications, vol.238, issue.3, pp.238-775, 1997. ,
DOI : 10.1006/bbrc.1997.7388
The Monkey and Human Uridine Diphosphate-Glucuronosyltransferase UGT1A9, Expressed in Steroid Target Tissues, Are Estrogen-Conjugating Enzymes, Endocrinology, vol.140, issue.7, pp.3292-302, 1999. ,
DOI : 10.1210/en.140.7.3292
Influence of Nonsynonymous Polymorphisms of UGT1A8 and UGT2B7 Metabolizing Enzymes on the Formation of Phenolic and Acyl Glucuronides of Mycophenolic Acid, Drug Metabolism and Disposition, vol.34, issue.9, pp.1539-1584, 2006. ,
DOI : 10.1124/dmd.106.010553
Effect of Mycophenolate Acyl-Glucuronide on Human Recombinant Type 2 Inosine Monophosphate Dehydrogenase, Clinical Chemistry, vol.55, issue.5, pp.986-93, 2009. ,
DOI : 10.1373/clinchem.2008.113936
The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes, Transplantation Proceedings, vol.33, issue.1-2, pp.1080-1081, 1933. ,
DOI : 10.1016/S0041-1345(00)02424-6
Pharmacokinetics and Protein Adduct Formation of the Pharmacologically Active Acyl Glucuronide Metabolite of Mycophenolic Acid in Pediatric Renal Transplant Recipients, Therapeutic Drug Monitoring, vol.24, issue.3, pp.390-399, 2002. ,
DOI : 10.1097/00007691-200206000-00011
ROLE OF MRP2 IN THE HEPATIC DISPOSITION OF MYCOPHENOLIC ACID AND ITS GLUCURONIDE METABOLITES: EFFECT OF CYCLOSPORINE, Drug Metabolism and Disposition, vol.34, issue.2, pp.261-267, 2006. ,
DOI : 10.1124/dmd.105.006122
The Role of Organic Anion???Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics, Clinical Pharmacology & Therapeutics, vol.87, issue.1, pp.100-108, 2010. ,
DOI : 10.1086/379378
URL : https://hal.archives-ouvertes.fr/inserm-00415314
MYCOPHENOLATE MOFETIL-INDUCED VILLOUS ATROPHY, Transplantation, vol.66, issue.8, pp.66-1115, 1998. ,
DOI : 10.1097/00007890-199810270-00027
Villous atrophy induced by mycophenolate mofetil in renal-transplant patients, Transplant International, vol.24, issue.8, pp.463-470, 2004. ,
DOI : 10.1056/NEJMra010852
Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea, Transplantation, vol.75, issue.5, 2003. ,
DOI : 10.1097/01.TP.0000053753.43268.F0
Determinants of Mycophenolic Acid Levels After Renal Transplantation, Therapeutic Drug Monitoring, vol.27, issue.4, pp.442-50, 2005. ,
DOI : 10.1097/01.ftd.0000167885.17280.6f
Plasma Concentrations of Mycophenolic Acid Acyl Glucuronide Are Not Associated with Diarrhea in Renal Transplant Recipients, American Journal of Transplantation, vol.44, issue.7, pp.1822-1853, 2007. ,
DOI : 10.1097/01.tp.0000235533.29300.e7
Cyclosporine Interacts with Mycophenolic Acid by Inhibiting the Multidrug Resistance-Associated Protein 2, American Journal of Transplantation, vol.41, issue.1, pp.987-94, 2005. ,
DOI : 10.1046/j.1523-1755.2001.00782.x
Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue, PROTEOMICS, vol.4, issue.9, pp.2728-2766, 2004. ,
DOI : 10.1002/pmic.200300836
Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex ,
VARIABLE EXPRESSION OF MRP2 (ABCC2) IN HUMAN PLACENTA: INFLUENCE OF GESTATIONAL AGE AND CELLULAR DIFFERENTIATION, Drug Metabolism and Disposition, vol.33, issue.7, pp.896-904, 2005. ,
DOI : 10.1124/dmd.104.003335
Characterization of the Cellular Localization, Expression Level, and Function of SNP Variants of MRP2/ABCC2, Pharmaceutical Research, vol.21, issue.5, pp.742-750, 2004. ,
DOI : 10.1023/B:PHAM.0000026422.06207.33
gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation, Pharmacogenomics, vol.8, issue.9 ,
DOI : 10.2217/14622416.8.9.1127
Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients, European Journal of Clinical Pharmacology, vol.28, issue.12, pp.1161-1170, 2007. ,
DOI : 10.1007/s00228-007-0380-7
Multidrug Resistance Protein 2 Genetic Polymorphisms Influence Mycophenolic Acid Exposure in Renal Allograft Recipients, Transplantation, vol.82, issue.8 ,
DOI : 10.1097/01.tp.0000235533.29300.e7
UGT1A9 275T>A/ 2152C>T polymorphisms correlate with low MPA exposure and acute rejection in ? ? ,
Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients, Xenobiotica, vol.2, issue.11, pp.1422-1458, 2008. ,
DOI : 10.1097/00008571-200405000-00008
Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8*2 variant allele, British Journal of Clinical Pharmacology, vol.34, issue.6, pp.675-83, 2010. ,
DOI : 10.1111/j.1365-2125.2010.03625.x
URL : https://hal.archives-ouvertes.fr/inserm-00446912
Genetic Polymorphisms of MRP2 and UGT2B7 and Gastrointestinal Symptoms in Renal Transplant Recipients Taking Mycophenolic Acid, Therapeutic Drug Monitoring, vol.31, issue.5, pp.542-550, 2009. ,
DOI : 10.1097/FTD.0b013e3181b1dd5e
A novel functional polymorphism in the uridine diphosphate???glucuronosyltransferase 2B7 promoter with significant impact on promoter activity, Clinical Pharmacology & Therapeutics, vol.75, issue.3, pp.223-256, 2004. ,
DOI : 10.1016/j.clpt.2003.10.006
Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients, Pharmacogenetics and Genomics, vol.17, issue.5, pp.321-351, 2007. ,
DOI : 10.1097/FPC.0b013e32801430f8
AcylMPAG Plasma Concentrations and Mycophenolic Acid-Related Side Effects in Patients Undergoing Renal Transplantation Are Not Related to the UGT2B7-840G>A Gene Polymorphism, Therapeutic Drug Monitoring, vol.PAP, issue.4, pp.439-483, 2008. ,
DOI : 10.1097/FTD.0b013e318180c709
Identification and functional characterization of UDP ,
Pharmacogenetic influences on mycophenolate therapy, Pharmacogenomics, vol.11, issue.3, pp.369-90, 2010. ,
DOI : 10.2217/pgs.10.9
Identification of common polymorphisms in the promoter of the UGT1A9 gene, Pharmacogenetics, vol.14, issue.8, pp.501-516, 2004. ,
DOI : 10.1097/01.fpc.0000114754.08559.27
The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients, Clin Pharmacol Ther, issue.4, pp.351-61, 2005. ,
Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil, Pharmacogenetics and Genomics, vol.20, issue.9, pp.537-580, 2010. ,
DOI : 10.1097/FPC.0b013e32833d8cf5
URL : https://hal.archives-ouvertes.fr/inserm-00494526
Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics, British Journal of Pharmacology, vol.272, issue.7, 2010. ,
DOI : 10.1111/j.1476-5381.2010.00987.x
Association of four DNA polymorphisms with acute rejection after kidney transplantation, Transplant International, vol.96, issue.9, pp.879-91, 2008. ,
DOI : 10.1111/j.1432-2277.2008.00679.x
IMPDH1 Gene Polymorphisms and Association With Acute Rejection in Renal Transplant Patients, Clinical Pharmacology & Therapeutics, vol.10, issue.5, pp.711-718, 2008. ,
DOI : 10.1038/sj.clpt.6100347
Correlation of IMPDH1 Gene Polymorphisms with Subclinical Acute Rejection and Mycophenolic Acid Exposure Parameters on Day 28 after Renal Transplantation, Basic & Clinical Pharmacology & Toxicology, vol.29, issue.2, pp.631-637, 2010. ,
DOI : 10.1111/j.1742-7843.2010.00542.x
Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs, Clinical Pharmacology and Therapeutics, vol.43, issue.6, pp.630-635, 1988. ,
DOI : 10.1038/clpt.1988.87
Review: Metabolism of Immunosuppressant Drugs, Current Drug Metabolism, vol.3, issue.3, pp.275-87, 2002. ,
DOI : 10.2174/1389200023337630
Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2?, European Journal of Clinical Pharmacology, vol.17, issue.2, pp.153-161, 2010. ,
DOI : 10.1007/s00228-009-0740-6
Clinical Pharmacokinetics of Tacrolimus, Clinical Pharmacokinetics, vol.29, issue.6, pp.404-434, 1995. ,
DOI : 10.2165/00003088-199529060-00003
The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects, Drug Metab Dispos, issue.6, pp.633-639, 1999. ,
EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO, Drug Metabolism and Disposition, vol.34, issue.5, pp.836-883, 2006. ,
DOI : 10.1124/dmd.105.008680
DISPOSITION OF TACROLIMUS IN ISOLATED PERFUSED RAT LIVER: INFLUENCE OF TROLEANDOMYCIN, CYCLOSPORINE, AND GG918, Drug Metabolism and Disposition, vol.31, issue.11, pp.1292-1297, 2003. ,
DOI : 10.1124/dmd.31.11.1292
Role of P-glycoprotein in the hepatic metabolism of tacrolimus, Xenobiotica, vol.16, issue.1, pp.1-13, 2006. ,
DOI : 10.3109/00498250500485115
Cyclosporin A, but Not Tacrolimus, Inhibits the Biliary Excretion of Mycophenolic Acid Glucuronide Possibly Mediated by Multidrug Resistance-Associated Protein 2 in Rats, Journal of Pharmacology and Experimental Therapeutics, vol.309, issue.3, pp.1029-1064, 2004. ,
DOI : 10.1124/jpet.103.063073
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nat Genet, issue.4, pp.383-91, 2001. ,
Pharmacogenetic differences and drug???drug interactions in immunosuppressive therapy, Expert Opinion on Drug Metabolism & Toxicology, vol.74, issue.8, pp.487-503, 2005. ,
DOI : 10.1016/S0006-2952(01)00911-X
Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis, Pharmacogenetics and Genomics, vol.20, issue.9 ,
DOI : 10.1097/FPC.0b013e32833ccd56
The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis, The Pharmacogenomics Journal, vol.11, issue.3 ,
DOI : 10.2165/11313380-000000000-00000
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients, Pharmacogenetics, vol.14, issue.3, pp.147-54, 2004. ,
DOI : 10.1097/00008571-200403000-00002
Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians, Transplantation, vol.79, issue.4, pp.79-499, 2005. ,
DOI : 10.1097/01.TP.0000151766.73249.12
Sirolimus and Tacrolimus Trough Concentrations and Dose Requirements after Kidney Transplantation in Relation to CYP3A5 and MDR1 Polymorphisms and Steroids, Transplantation, vol.80, issue.7, pp.80-977, 2005. ,
DOI : 10.1097/01.TP.0000174131.47469.D2
Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients, Transplantation, vol.78, issue.8 ,
DOI : 10.1097/01.TP.0000137789.58694.B4
Opportunities to optimize tacrolimus therapy in solid organ transplantation ,
Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing, Clinical Pharmacology & Therapeutics, vol.87, issue.6, pp.721-727, 2010. ,
DOI : 10.1097/00007890-200212150-00002
Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome?, Clinical Pharmacology & Therapeutics, vol.87, issue.6, pp.640-641, 2010. ,
DOI : 10.1681/ASN.2009020192
Pharmacogenetic vs. Concentration-Controlled Optimization of Tacrolimus Dosing in Renal Allograft Recipients, Clinical Pharmacology & Therapeutics, vol.82, issue.5, pp.595-601, 2010. ,
DOI : 10.1038/clpt.2010.129
Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II, Clinical Pharmacokinetics, vol.14, issue.11, pp.49-207, 2010. ,
DOI : 10.2165/11317550-000000000-00000
Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients, Pharmacogenetics and Genomics, vol.18, issue.4, pp.307-322, 2008. ,
DOI : 10.1097/FPC.0b013e3282f7046f
Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene, Clinical Pharmacology & Therapeutics, vol.72, issue.5, pp.584-94, 2002. ,
DOI : 10.1067/mcp.2002.129196
Haplotypic Structure of ABCB1/MDR1 Gene Modifies the Risk of the Acute Allograft Rejection in Renal Transplant Recipients, Transplantation, vol.86, issue.9 ,
DOI : 10.1097/TP.0b013e318187c4d1
ABCB1 Genotype of the Donor but Not of the Recipient Is a Major Risk Factor for Cyclosporine-Related Nephrotoxicity after Renal Transplantation, Journal of the American Society of Nephrology, vol.16, issue.5, pp.1501-1512, 2005. ,
DOI : 10.1681/ASN.2004100882
Donor P-gp Polymorphisms Strongly Influence Renal Function and Graft Loss in a Cohort of Renal Transplant Recipients on Cyclosporine Therapy in a Long-Term Follow-Up, Clinical Pharmacology & Therapeutics, vol.50, issue.1, pp.95-100, 2010. ,
DOI : 10.1086/379378
URL : https://hal.archives-ouvertes.fr/inserm-00462541
Donor Age and Renal P-Glycoprotein Expression Associate with Chronic Histological Damage in Renal Allografts, Journal of the American Society of Nephrology, vol.20, issue.11, pp.2468-80, 2009. ,
DOI : 10.1681/ASN.2009020192
The Pharmacogenetics of Calcineurin Inhibitor???Related Nephrotoxicity, Therapeutic Drug Monitoring, vol.32, issue.4, pp.387-93, 2010. ,
DOI : 10.1097/FTD.0b013e3181e44244
Calcineurin mutants render T lymphocytes resistant to cyclosporin A, Mol Pharmacol, issue.3, pp.506-517, 1996. ,
A search for cyclophilin-A gene variants in cyclosporine A-treated renal transplanted patients, Clinical Transplantation, vol.3, issue.6, 2008. ,
DOI : 10.1111/j.1399-0012.2008.00867.x
Use of the New Proliferation Signal Inhibitor Everolimus in Renal Transplant Patients in Spain: Preliminary Results of the EVERODATA Registry, Transplantation Proceedings, vol.39, issue.7, pp.2157-2166, 2007. ,
DOI : 10.1016/j.transproceed.2007.07.071
Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group, Lancet, vol.15, issue.9225, pp.356-194, 2000. ,
Sirolimus to replace calcineurin inhibitors? Too early yet, The Lancet, vol.373, issue.9671, pp.373-1235, 2009. ,
DOI : 10.1016/S0140-6736(09)60709-1
Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine, J Pharmacol Exp Ther, issue.3, pp.1104-1116, 1998. ,
Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat, Drug Metab Dispos, issue.5, pp.753-61, 1992. ,
Metabolism of Sirolimus in the Presence or Absence of Cyclosporine by Genotyped Human Liver Microsomes and Recombinant Cytochromes P450 3A4 and 3A5, Drug Metabolism and Disposition, vol.35, issue.3, pp.350-355, 2007. ,
DOI : 10.1124/dmd.106.012161
Pharmacokinetic and Pharmacodynamic Interactions Between the Immunosuppressant Sirolimus and the Lipid-Lowering Drug Ezetimibe in Healthy Volunteers, Clinical Pharmacology & Therapeutics, vol.60, issue.6, pp.663-670, 2010. ,
DOI : 10.1177/0091270006289851
Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine???sirolimus interaction, Kidney International, vol.70, issue.6, pp.1019-1044, 2006. ,
DOI : 10.1038/sj.ki.5001649
Consequences of Genetic Polymorphisms for Sirolimus Requirements After Renal Transplant in Patients on Primary Sirolimus Therapy, American Journal of Transplantation, vol.8, issue.3, pp.595-603, 2005. ,
DOI : 10.1177/0091270003043006001
CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients, Clinical Pharmacology & Therapeutics, vol.80, issue.1, pp.51-60, 2006. ,
DOI : 10.1016/j.clpt.2006.03.012
Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients, Biopharmaceutics & Drug Disposition, vol.14, issue.1, pp.1-5, 2008. ,
DOI : 10.1002/bdd.577
A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity, Science, vol.315, issue.5811, pp.315-525, 2007. ,
DOI : 10.1126/science.1135308
Rapamycins: Mechanisms of Action and Cellular Resistance, Cancer Biology & Therapy, vol.2, issue.3, pp.222-254, 2002. ,
DOI : 10.4161/cbt.2.3.360
Identification and Functional Characterization of a New Human Kidney-Specific H+/Organic Cation Antiporter, Kidney-Specific Multidrug and Toxin Extrusion 2, Journal of the American Society of Nephrology, vol.17, issue.8, pp.2127-2162, 2006. ,
DOI : 10.1681/ASN.2006030205
A human transporter protein that mediates the final excretion step for toxic organic cations, Proceedings of the National Academy of Sciences, vol.102, issue.50, 2005. ,
DOI : 10.1073/pnas.0506483102